Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers-Reply

JAMA Oncol. 2020 Dec 1;6(12):1983. doi: 10.1001/jamaoncol.2020.4824.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Acrylamides
  • Aniline Compounds
  • Bevacizumab
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Progression-Free Survival

Substances

  • Acrylamides
  • Aniline Compounds
  • Bevacizumab
  • osimertinib
  • EGFR protein, human
  • ErbB Receptors